Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

3.420 +0.270 (+8.57%)
Official Closing Price Updated: 7:00 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,006,076
Open 3.210
Bid (Size) 3.480 (100)
Ask (Size) 3.490 (75)
Prev. Close 3.150
Today's Range 3.150 - 3.480
52wk Range 1.540 - 3.480
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
NUVB Sales Jump 1,043% on Drug Launch
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
+32.0%
+32.0%
1 Month
+44.3%
+44.3%
3 Month
+37.9%
+37.9%
6 Month
+81.0%
+81.0%
1 Year
+13.6%
+13.6%

More News

Read More
Nuvation Bio Inc (NYSE:NUVB) Reports Mixed Q2 2025 Results with Strong Revenue Beat but Cautious Market Reaction
Via Chartmill
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio
Via Business Wire
Earnings Scheduled For August 7, 2025
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
From Nuvation Bio
Via Business Wire
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
From Nuvation Bio
Via Business Wire
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
From Nuvation Bio
Via Business Wire
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
Via Benzinga
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at The Citizens Life Sciences Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
Apple To $280? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga

Frequently Asked Questions

Is Nuvation Bio Inc. Class A Common Stock publicly traded?
Yes, Nuvation Bio Inc. Class A Common Stock is publicly traded.
What exchange does Nuvation Bio Inc. Class A Common Stock trade on?
Nuvation Bio Inc. Class A Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Nuvation Bio Inc. Class A Common Stock?
The ticker symbol for Nuvation Bio Inc. Class A Common Stock is NUVB on the New York Stock Exchange
What is the current price of Nuvation Bio Inc. Class A Common Stock?
The current price of Nuvation Bio Inc. Class A Common Stock is 3.420
When was Nuvation Bio Inc. Class A Common Stock last traded?
The last trade of Nuvation Bio Inc. Class A Common Stock was at 09/04/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.